Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2013
08/15/2013WO2013117288A1 Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
08/15/2013WO2013117285A1 Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors
08/15/2013WO2013117235A1 Maternal supplement to enhance immune system of an infant
08/15/2013WO2013117234A1 Maternal composition for enhancing immune system
08/15/2013WO2013117137A1 Lupane triterpenoid derivatives and pharmaceutical use thereof
08/15/2013WO2013117008A1 Composition comprising hawthorn and phytosterols
08/15/2013WO2013117007A1 Composition comprising phytosterols and kudzu for cardiovascular diseases
08/15/2013WO2013116949A1 Glycosylated antitumor ether lipids as novel cancer stem cell cytotoxic agents
08/15/2013WO2013116948A1 Indolizine derivatives
08/15/2013WO2013098416A3 Pain relief compounds
08/15/2013WO2013096496A3 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
08/15/2013WO2013096429A3 Methods and compositions for reducing body fat and adipocytes
08/15/2013WO2013095042A3 Granule containing imatinib mesylate, immediate release oral tablet composition containing same, and preparation method thereof
08/15/2013WO2013092936A3 Use of 5-aminolevulinic acid and esters, in combination with a vitamin d derivative or analog in photochemotherapy, and their uses in treating acne
08/15/2013WO2013074059A3 Cytosine deaminase modulators for enhancement of dna transfection
08/15/2013WO2013072766A3 Process for cabazitaxel and intermediates thereof
08/15/2013WO2013072763A3 Non-sensitizing transdermal clonidine patch
08/15/2013WO2013064703A3 Fkbp subtype-specific rapamycin analogue for use in treatment of diseases
08/15/2013WO2013062964A3 Methanol derivatives as trpv3 modulators
08/15/2013WO2013061328A3 Methods of treating cancer
08/15/2013WO2013042135A8 Heteroaryl compounds as 5-ht4 receptor ligands
08/15/2013WO2013042065A4 Inhibitors of type ii ribosome inactivating proteins
08/15/2013WO2013041810A9 Stable, low-toxicity, sterilizable composition for ophthalmic dying
08/15/2013WO2012122028A3 Pyrazinoisoquinoline compounds
08/15/2013WO2012068560A3 4-quinolinemethanols as anti-malarial agents
08/15/2013WO2012019165A3 Methods of inhibition of protein fucosylation in vivo using fucose analogs
08/15/2013WO2011084848A3 Prodrugs of heteraromatic compounds
08/15/2013US20130211490 Everolimus Eluting Bioabsorbable Renal Artery Stent For Renal Cancer And Inflammatory Disorders
08/15/2013US20130211368 Microfabricated nanopore device for sustained release of therapeutic agent
08/15/2013US20130210929 Topical germicidal compositions
08/15/2013US20130210927 Method of Administering an Interomone to an Animal to Modify the Animals Behavior over an Extended Period of Time
08/15/2013US20130210926 Glycyrrhetinic acid derivatives
08/15/2013US20130210925 Subunguicide, and method for treating onychomycosis
08/15/2013US20130210924 Dosage Regimen of Diaryl Sulfide Derivatives
08/15/2013US20130210922 Stable ready to use injectable paracetamol formulation
08/15/2013US20130210920 Desensitizing drug product
08/15/2013US20130210917 Nitrated Lipids and Methods of Making and Using Thereof
08/15/2013US20130210916 Thermally stable oil-in-water emulsions containing an oil that contains polyunsaturated fatty acids
08/15/2013US20130210914 Methods of therapeutic monitoring of nitrogen scavenging drugs
08/15/2013US20130210911 Method and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor
08/15/2013US20130210910 Compositions suitable for the topical treatment of fungal infections of the skin and nails
08/15/2013US20130210907 Method for preventing or treating enterochromaffin cell hyperplasia-related diseases by quercetin administration
08/15/2013US20130210905 Selective Ablation of Pain-Sensing Neurons by Administration of a Vanilloid Receptor Agonist
08/15/2013US20130210903 Aptamers to glycoprotein vi
08/15/2013US20130210900 ARID1A and PPP2R1A Mutations in Cancer
08/15/2013US20130210899 Method and Therapeutic for the Treatment and Regulation of Memory Formation
08/15/2013US20130210898 Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
08/15/2013US20130210892 Method of Treatment
08/15/2013US20130210890 Cancer therapy
08/15/2013US20130210889 Composition and method for inner ear sensory hair cell regeneration and replacement
08/15/2013US20130210888 Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1
08/15/2013US20130210887 Dendrimers as non-viral vehicles for gene therapy
08/15/2013US20130210884 Methods for Identifying Analgesic Agents
08/15/2013US20130210879 Formulations of bendamustine
08/15/2013US20130210876 Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
08/15/2013US20130210875 Novel binding site of IKK-beta
08/15/2013US20130210874 Dual-acting antihypertensive agents
08/15/2013US20130210869 Method of increasing the extent of absorption of tizanidine
08/15/2013US20130210868 Stable topical compositions for 1,2,4-thiadiazole derivatives
08/15/2013US20130210867 Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
08/15/2013US20130210866 Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
08/15/2013US20130210862 Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
08/15/2013US20130210861 Methods and compositions for managing cardiovascular disease associated with chronic kidney disease
08/15/2013US20130210860 Prophylactic and/or therapeutic agent against lymphedema
08/15/2013US20130210858 Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists
08/15/2013US20130210856 Compositions and methods for treating sleep disorders
08/15/2013US20130210855 2 x 2 x 2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod
08/15/2013US20130210852 Methods for treating infection
08/15/2013US20130210851 Crystalline forms of a hexahydrofuro[3,4-c]quinoline derivative
08/15/2013US20130210850 Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
08/15/2013US20130210849 Methods for treating disorders associated with mGLU receptors including addiction and depression
08/15/2013US20130210847 Process for the preparation of nilotinib
08/15/2013US20130210843 Predictive marker for egfr inhibitor treatment
08/15/2013US20130210842 Pure erlotinib
08/15/2013US20130210841 Mucoadhesive buccal tablets for the treatment of orofacial herpes
08/15/2013US20130210840 Anti-Cellulite Composition and Method of Treating Cellulite
08/15/2013US20130210835 Pharmaceutical compositions
08/15/2013US20130210832 1h-imidazo[4,5-c]quinolines
08/15/2013US20130210830 Therapeutic compositions
08/15/2013US20130210829 Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
08/15/2013US20130210826 Methods for treating pain
08/15/2013US20130210824 Substituted fused imidazoles and pyrazoles and use thereof
08/15/2013US20130210819 Quinazoline derivatives
08/15/2013US20130210818 Novel Heterocyclic Compounds and Uses Thereof
08/15/2013US20130210813 Male Contraceptive Compositions and Methods of Use
08/15/2013US20130210810 Protein Kinase C Inhibitors and Uses Thereof
08/15/2013US20130210809 Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
08/15/2013US20130210808 Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
08/15/2013US20130210807 Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors.
08/15/2013US20130210805 Quinazolinone-type compounds as crth2 antagonists
08/15/2013US20130210798 Soluble guanylate cyclase activators
08/15/2013US20130210797 Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension
08/15/2013US20130210795 Substituted dicyanopyridines and use thereof
08/15/2013US20130210794 Nanostructured ezetimibe compositions, process for the preparation thereof and pharmaceutical compositions containing them
08/15/2013US20130210792 Method of treating disorder related to high cholesterol concentration
08/15/2013US20130210791 Testosterone gel and method of use
08/15/2013US20130210790 Testosterone gel and method of use
08/15/2013US20130210789 Testosterone gel and method of use
08/15/2013US20130210788 Method for post coital contraception in overweight or obese female subjects using ulipristal acetate
08/15/2013US20130210787 C-3 cycloalkenyl triterpenoids with hiv maturation inhibitory activity
1 ... 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 ... 7860